AN2 Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
ANTX$4.000.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
Exhibit Index
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation. | S-1 | 333-263295 | 3.2 | March 4 2022 |
| 3.2 | Amended and Restated Bylaws. | S-1 | 333-263295 | 3.4 | March 4, 2022 |
| 4.1 | Form of Common Stock Certificate. | S-1 | 333-263295 | 4.1 | March 21, 2022 |
| 4.2 | Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated March 5, 2021. | S-1 | 333-263295 | 4.2 | March 4, 2022 |
| 4.3 | Description of Securities | 10-K | 001-41331 | 4.3 | March 29, 2023 |
| 10.1# | AN2 Therapeutics, Inc. 2017 Equity Incentive Plan, as amended. | S-1 | 333-263295 | 10.1 | March 4, 2022 |
| 10.2# | Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise and Early Exercise Stock Purchase Agreement under the AN2 Therapeutics, Inc. 2017 Equity Incentive Plan. | S-1 | 333-263295 | 10.2 | March 4, 2022 |
| 10.3#* | AN2 Therapeutics, Inc. 2022 Equity Incentive Plan. | ||||
| 10.4# | Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan. | S-1 | 333-263295 | 10.4 | March 4, 2022 |
| 10.5#* | Form of Restricted Stock Unit Grant Notice and Award Agreement under the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan. | ||||
| 10.6#* | AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan. | ||||
| 10.7# | AN2 Therapeutics, Inc. 2022 Non-Employee Director Compensation Policy. | S-1 | 333-263295 | 10.7 | March 4, 2022 |
| 10.8# | AN2 Therapeutics, Inc. Officer Severance Plan. | S-1 | 333-263295 | 10.8 | March 4, 2022 |
| 10.9# | Form of Indemnity Agreement by and between the Registrant and its directors and executive officers. | S-1 | 333-263295 | 10.9 | March 4, 2022 |
| 10.10# | Offer Letter by and between the Registrant and Eric Easom, dated November 19, 2019. | S-1 | 333-263295 | 10.10 | March 4, 2022 |
| 10.11# | Offer Letter by and between the Registrant and Lucy Day, dated November 19, 2019. | S-1 | 333-263295 | 10.11 | March 4, 2022 |
| 10.12# | Offer Letter by and between the Registrant and Sanjay Chanda, dated November 19, 2019. | S-1 | 333-263295 | 10.12 | March 4, 2022 |
| 10.13‡ | License Agreement by and between the Registrant and Anacor Pharmaceuticals, Inc., dated November 20, 2019, as amended on December 3, 2021. | S-1 | 333-263295 | 10.13 | March 4, 2022 |
| 10.14‡ | License Agreement by and between the Registrant and Brii Biosciences Limited, dated November 20, 2019. | S-1 | 333-263295 | 10.14 | March 4, 2022 |
| 10.15 | Amended and Restated Global Health Agreement by and among the Registrant, Adjuvant Global Health Technology Fund L.P., and Adjuvant Global Health Technology Fund DE L.P., dated March 5, 2021. | S-1 | 333-263295 | 10.15 | March 4, 2022 |
| 10.16# | Offer Letter by and between the Registrant and Joshua Eizen, dated September 19, 2022. | 10-Q | 001-41331 | 10.1 | November 9, 2022 |
| 10.17# | Offer Letter by and between the Registrant and Kevin Krause, dated November 19, 2019. | 10-K | 001-41331 | 10.17 | March 29, 2023 |
| 10.18# | Offer Letter by and between the Registrant and Paul Eckburg, dated April 30, 2021. | 10-K | 001-41331 | 10.18 | March 29, 2023 |
| Incorporated by Reference | |||||
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date |
| 23.1* | Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm. | ||||
| 24.1* | Power of Attorney (incorporated by reference to the signature page to this Annual Report on Form 10-K.) | ||||
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1*† | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2*† | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 97.1* | Compensation Recovery Policy. | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document** | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document** | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document** | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document** | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document** | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
- Filed herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.